Leonie Klimpke
Director Financiero/CFO en Cavalry Ventures Management GmbH .
Perfil
Leonie Klimpke is currently the Head of Finance at Cavalry Ventures Management GmbH since 2022.
Previously, she worked as a Finance Manager at Eternygen GmbH from 2016 to 2020.
Ms. Klimpke completed her undergraduate degree at Vrije Universiteit Amsterdam in 2010 and her graduate degree at École des Hautes Études Commerciales de Paris in 2014.
Cargos activos de Leonie Klimpke
Empresas | Cargo | Inicio |
---|---|---|
Cavalry Ventures Management GmbH
Cavalry Ventures Management GmbH Investment ManagersFinance Cavalry Ventures Management GmbH (Cavalry) is a venture capital firm founded in 2015 by Rouven Dresselhaus. The firm is headquartered in Berlin, Germany. | Director Financiero/CFO | 01/02/2020 |
Antiguos cargos conocidos de Leonie Klimpke.
Empresas | Cargo | Fin |
---|---|---|
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | Corporate Officer/Principal | 28/02/2020 |
Formación de Leonie Klimpke.
École des Hautes Études Commerciales de Paris | Graduate Degree |
Vrije Universiteit Amsterdam | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Cavalry Ventures Management GmbH
Cavalry Ventures Management GmbH Investment ManagersFinance Cavalry Ventures Management GmbH (Cavalry) is a venture capital firm founded in 2015 by Rouven Dresselhaus. The firm is headquartered in Berlin, Germany. | Finance |
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | Health Technology |
- Bolsa de valores
- Insiders
- Leonie Klimpke